OLATHE, Kan. and MISSION VIEJO, Calif., Dec. 28, 2016 (GLOBE NEWSWIRE) -- Hooper Holmes, Inc. (NYSE MKT:HH), a national leader in corporate wellness and health screenings and MYnd Analytics, Inc. (OTCQB:MYAN), a predictive analytics company that has developed a decision support system to help physicians reduce trial and error treatment in mental health, announced today that they have entered into an agreement whereby the Hooper Holmes national network of health professionals will provide on-site or in-home EEG services for MYnd Analytics nationally.
“We are thrilled to leverage our nationwide network to assist MYnd to provide physicians with a decision support tool to enable them to provide more personalized care to patients based on their brain waves. The trained health professionals will deliver a standard electroencephalogram (EEG) test, measuring the electrical activity of the brain to predict the likelihood of their brain to certain psychotropic medications for the treatment of behavioral disorders such as depression, anxiety, bipolar disorder, and post-traumatic stress disorder,” said Henry Dubois, President and CEO of Hooper Holmes, Inc. “Offering additional services that give practitioners clinical decision support tools in mental health clearly enhances our value proposition to our corporate clientele.”
"Based on our positive clinical trial results and the high incidence of patients who have been suffering from depression, PTSD, and other behavioral health disorders, we believe it is critical to rapidly expand our footprint and offer our services nationally to assist physicians to determine the most effective treatment for their patients based on their individual brain waves. Utilizing the Hooper Holmes nationwide services expands our ability to provide more services to more patients," said George C. Carpenter, IV, MYnd Analytics' CEO.
About Hooper Holmes
Hooper Holmes mobilizes a national network of health professionals to provide on-site health screenings, laboratory testing, risk assessment and sample collection services to wellness and disease management companies, employers and brokers, government organizations and academic institutions nationwide. Under the Accountable Health Solutions brand, the Company combines smart technology, healthcare and behavior change expertise to offer comprehensive health and wellness programs that improve health, increase efficiencies and reduce healthcare delivery costs.
About MYnd Analytics, Inc.
MYnd Analytics, Inc. (www.myndanalytics.com) provides a mental health decision support system that utilizes a unique set of reference data and analytic tools for clinicians and researchers in psychiatry. While treatment for mental disorders has doubled in the last 20 years, it is estimated that 17 million Americans have failed two or more medication therapies for their mental disorders. The Company’s Psychiatric EEG Evaluation Registry, or PEER Online, is a registry and reporting platform that allows medical professionals to exchange treatment outcome data for patients referenced to objective neurophysiology data obtained through a standard electroencephalogram (EEG). Based on the Company’s original physician-developed database, there are now more than 38,000 outcomes for over 10,000 unique patients in the PEER registry. The goal of PEER Online is to provide objective, personalized data to assist physicians in the selection of appropriate medications.
To read more about the benefits of this patented technology for patients, physicians and payers, please visit www.myndanalytics.com.
Safe Harbor Statement Under the Private Securities Litigation Reform Act of 1995
Except for the historical information contained herein, the matters discussed are forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements are statements that are not historical facts. Such forward-looking statements are subject to significant risks and uncertainties that are subject to change based on various factors (many of which are beyond MYnd Analytics' control), which could cause actual results to differ from the forward-looking statements. Such statements may include, without limitation, statements with respect to MYnd Analytics' plans, objectives, projections, expectations and intentions and other statements identified by words such as “projects,” “may,” “will,” “could,” “would,” “should,” “continue,” “seeks,” “aims,” “predicts,” “believes,” “expects,” “anticipates,” “estimates,” “intends,” “plans,” “potential” or similar expressions (including their use in the negative); the ability of our decision support system to help physicians reduce trial and error treatment in mental health patients; our ability to expand our footprint and offer our services nationally; our ability to assist physicians in determining the most effective treatment for their patients based on individual brain waves; our ability to successfully implement our arrangement with Hooper Holmes to expand our services; the ability of PEER Online to meet its goal of providing objective, personalized data to assist physicians in the selection of appropriate medications; our ability to support commercialization of the PEER product; and other statements that are not historical. These forward-looking statements involve risks and uncertainties as set forth in the Company's filings with the Securities and Exchange Commission. These risks and uncertainties could cause actual results to differ materially from any forward-looking statements made herein.